ANAB

AnaptysBio (ANAB)

About AnaptysBio (ANAB)

AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

Details

Daily high
$32.32
Daily low
$31.08
Price at open
$32.32
52 Week High
$41.31
52 Week Low
$13.36
Market cap
949.2M
Dividend yield
0.00%
Volume
316,440
Avg. volume
306,925
P/E ratio
-4.96

AnaptysBio News

Details

Daily high
$32.32
Daily low
$31.08
Price at open
$32.32
52 Week High
$41.31
52 Week Low
$13.36
Market cap
949.2M
Dividend yield
0.00%
Volume
316,440
Avg. volume
306,925
P/E ratio
-4.96